Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease

New England Journal of Medicine

Volumn 348, Issue 7, 2003, Pages 601-608

  Baert, Filip ^a   Noman, Maja ^a   Vermeire, Severine ^a   Van Assche, Gert ^a   D'Haens, Geert ^a   Carbonez, An ^b   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PROMETHAZINE;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG INFUSION; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MYALGIA; PREDICTION; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037434552     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020888     Document Type: Article

References (18)

1. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-35.
2. Kutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
5. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
6. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
7. Farrell PJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
8. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13:Suppl 4:16-22.
9. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 2001;7:Suppl 1:S17-S22.
10. Infliximab: summary of product characteristics. Malvern, Pa.: Centocor, January 17, 2002.
11. Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
12. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
13. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723-51.
14. Farrell RJ, Alsahli M, Falchuk KR, Peppercorn MA, Michetti P. Human and-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy. Gastroenterology 2001;120:Suppl 1:A-69. abstract.
15. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355:735-40.
16. Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol 1998;81:105-16, 119.
17. Clark M. Antibody humanization: a case of the 'emperor's new clothes'? Immunol Today 2000;21:397-402.
18. Renner C, Hartmann F, Pfreundschuh M. The future of monoclonal antibody engineering. Ann Hematol 2001;80:Suppl 3:B127-B129.